{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-25-000039","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.811747+00:00","generated_at":"2026-05-23T04:04:39.205618+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Nautilus Q1 net loss $16.6M, operating expenses down 13% YoY","bullets":["Net loss $16.6M, improved from $18.7M in Q1 2024.","Operating expenses $18.8M, down 13% from $21.6M prior year.","Cash, equivalents, and investments $192.8M as of March 31, 2025.","CEO reports progress on Tau proteoform assay toward commercial launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-25-000039","json":"https://secwatch.observer/filing/0001808805-25-000039.json","markdown":"https://secwatch.observer/filing/0001808805-25-000039.md","text":"https://secwatch.observer/filing/0001808805-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000039/0001808805-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880525000039/naut-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:04:39.205618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}